RxDoctor Payments Data

Chris Raphtis, MD

Ophthalmology · Warren, MINPI 1720073182

Payments from drug & device makers

$789in general payments, 2019–2025

Across 15 payments — averaging $52.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$175
  • Alcon$168
  • Ocular Therapeutix, Inc.$148
  • Tarsus Pharmaceuticals, Inc.$118
  • Bausch & Lomb Americas Inc.$91
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$45
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$789 in reported general payments places this provider in the 40th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$131,893
Medicare patients
506
Services billed
1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost47$29,174
Restasis MultidoseCyclosporine11$14,420
Brimonidine Tartrate73$10,540
Lotemax SmLoteprednol Etabonate39$9,554
Latanoprost303$7,613
Bromfenac Sodium30$6,773
Brinzolamide21$5,626
ProlensaBromfenac Sodium16$5,109
SimbrinzaBrinzolamide/Brimonidine Tart14$4,918
Timolol Maleate146$2,724
Prednisolone Acetate53$2,542
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,165
Dorzolamide Hcl50$2,117
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha110$1,336
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis Multidose$18$43,59558 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa$45$14,66355 claims
AlconSimbrinza$168$4,91814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →